

Immune checkpoint inhibitor-induced colitis: A comprehensive review

World Journal of Clinical Cases

7, 405-418

DOI: [10.12998/wjcc.v7.i4.405](https://doi.org/10.12998/wjcc.v7.i4.405)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Liver graft rejection following immune checkpoint inhibitors treatment: a review. <i>Medical Oncology</i> , 2019, 36, 94.	1.2	27
2	Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. <i>BMC Cancer</i> , 2019, 19, 1019.	1.1	48
3	Testing Immune-Related Adverse Events in Cancer Immunotherapy. <i>Clinics in Laboratory Medicine</i> , 2019, 39, 669-683.	0.7	3
4	Concurrent therapy with immune checkpoint inhibitors and TNF α blockade in patients with gastrointestinal immune-related adverse events. , 2019, 7, 226.		89
5	Cardiotoxicity from immune checkpoint inhibitors. <i>IJC Heart and Vasculature</i> , 2019, 25, 100420.	0.6	79
6	Immune checkpoint inhibitor-related luminal GI adverse events. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 881-892.	0.5	24
7	Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-2.	0.2	3
8	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2019, 26, 96.	2.6	26
9	Radiologic Imaging of Bowel Infections. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 33-45.	0.7	8
10	Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab. <i>American Journal of Therapeutics</i> , 2020, 27, e415-e417.	0.5	1
11	Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9165.	1.8	20
12	Non-neoplastic colorectal disease biopsies: evaluation and differential diagnosis. <i>Journal of Clinical Pathology</i> , 2020, 73, 783-792.	1.0	8
13	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
14	Immune checkpoint inhibitor-induced enteritis assessed using capsule endoscopy. <i>JGH Open</i> , 2020, 4, 1231-1232.	0.7	3
15	Gastrointestinal side effects of cancer treatments. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232097035.	1.1	41
16	The role and economics of immunotherapy in solid tumour management. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 2020-2024.	0.5	4
17	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 109996.	2.5	35
19	Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. <i>Current Oncology Reports</i> , 2020, 22, 39.	1.8	199

#	ARTICLE	IF	CITATIONS
20	Impending infliximab access crisis: a case of steroidâ€refractory, relapsing immunotherapyâ€induced colitis responsive to infliximab. <i>Internal Medicine Journal</i> , 2020, 50, 767-768.	0.5	4
21	Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review. <i>Seminars in Hematology</i> , 2020, 57, 13-18.	1.8	11
22	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. <i>Oncologist</i> , 2020, 25, 669-679.	1.9	30
23	Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. <i>Gastroenterology Report</i> , 2020, 8, 25-30.	0.6	41
24	The Complex Interplay Between Inflammatory Bowel Disease and Malignancy. <i>Current Gastroenterology Reports</i> , 2020, 22, 13.	1.1	10
25	Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. <i>Annals of Surgical Oncology</i> , 2020, 27, 1533-1545.	0.7	6
26	Immune Checkpoint Inhibitorâ€Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, <i>Helicobacter pylori</i> Gastritis and Celiac Disease. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 191-200.	1.2	23
27	Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 140-149.	2.0	15
28	Colitis After CAR T-Cell Therapy for Refractory Large B-Cell Lymphoma Responds to Anti-Integrin Therapy. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e45-e46.	0.9	5
29	Collagenous colitis and atezolizumab therapy: an atypical case. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 165-169.	0.4	9
30	Vedolizumab for steroid & infliximab refractory immune checkpoint inhibitor associated colitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101604.	0.7	4
31	Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2385-2388.	2.0	3
32	Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab002.	0.3	16
33	Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia. <i>Science Progress</i> , 2021, 104, 003685042199730.	1.0	3
34	Severe colitis induced by pembrolizumab in a patient with advanced hypopharyngeal squamous cell carcinoma: A case report of an immune-related adverse event. <i>Journal of Cancer Research and Practice</i> , 2021, 8, 113.	0.2	1
35	Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEERâ€Medicare database. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862199127.	1.0	1
36	Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2761-2769.	2.0	7
37	ILâ€17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 159-168.	2.3	28

#	ARTICLE	IF	CITATIONS
38	Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. <i>Cells</i> , 2021, 10, 327.	1.8	37
39	CT imaging findings of anti-PD-1 inhibitor-related enterocolitis.. <i>Abdominal Radiology</i> , 2021, 46, 3033-3043.	1.0	4
40	Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. <i>American Journal of Clinical Pathology</i> , 2021, 156, 214-228.	0.4	15
41	Calcineurin inhibitors in steroid and anti-TNF-alpha refractory immune checkpoint inhibitor colitis. <i>JGH Open</i> , 2021, 5, 558-562.	0.7	9
42	PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours. <i>Endocrine Pathology</i> , 2021, 32, 408-414.	5.2	12
43	Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. <i>Healthcare (Switzerland)</i> , 2021, 9, 418.	1.0	5
44	Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study. <i>Gastroenterology Y Hepatologia (English Edition)</i> , 2021, 44, 261-268.	0.0	3
45	Chemotherapy-induced bowel ischemia: diagnostic imaging overview. <i>Abdominal Radiology</i> , 2022, 47, 1556-1564.	1.0	7
46	Efectos adversos inmunomediados gastrointestinales y hepáticos inducidos por los inhibidores del punto de control inmunitario: estudio descriptivo observacional. <i>Gastroenterology Y Hepatologia</i> , 2021, 44, 261-268.	0.2	8
47	Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 643255.	2.2	6
48	Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review. <i>BMC Gastroenterology</i> , 2021, 21, 227.	0.8	7
49	Histopathology of Gastrointestinal Immune-related Adverse Events. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, e15-e26.	2.1	7
50	Neurological Immunotoxicity from Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6716.	1.8	9
51	DCLK1 isoforms and aberrant Notch signaling in the regulation of human and murine colitis. <i>Cell Death Discovery</i> , 2021, 7, 169.	2.0	14
52	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2752-2765.	1.3	5
53	A case of immune checkpoint inhibitor-related colitis with a distinctive endoscopic finding of colonic pseudolipomatosis. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1431-1436.	0.4	6
54	Intestinal immune compartmentalization: implications of tissue specific determinants in health and disease. <i>Mucosal Immunology</i> , 2021, 14, 1259-1270.	2.7	26
55	Laryngeal Cancer With Lung Metastases Showing Long-Term Complete Response and Delayed Immune-Related Adverse Event After Nivolumab Discontinuation. <i>Ear, Nose and Throat Journal</i> , 2021, , 014556132110310.	0.4	2

#	ARTICLE	IF	CITATIONS
56	Real-World Study of Treatment with Pembrolizumab Among Patients with Advanced Urothelial Tract Cancer in Denmark. <i>Bladder Cancer</i> , 2021, 7, 413-425.	0.2	1
57	Immune checkpoint inhibitor induced colitis: A nationwide population-based study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101778.	0.7	7
58	Non-invasive Detection of Immunotherapy-Induced Adverse Events. <i>Clinical Cancer Research</i> , 2021, 27, 5353-5364.	3.2	13
59	Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. <i>Journal of Immunotherapy</i> , 2021, 44, 325-334.	1.2	12
60	Perforated appendicitis induced by pembrolizumab. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	5
61	Immunotherapy-induced coeliac disease in curative lung cancer. <i>BMJ Case Reports</i> , 2021, 14, e243406.	0.2	1
62	Flexible sigmoidoscopy may be sufficient for initial evaluation of suspected immunotherapy-mediated colitis: A cross-sectional study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 284-290.	1.4	5
63	ROR γ t Promotes Foxp3 Expression by Antagonizing the Effector Program in Colonic Regulatory T Cells. <i>Journal of Immunology</i> , 2021, 207, 2027-2038.	0.4	24
64	Approach to the adult patient with chronic diarrhea: A literature review. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2021, 86, 387-402.	0.1	7
65	Abordaje de la diarrea crÃ³nica en el adulto: RevisiÃ³n de la literatura. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2021, 86, 387-402.	0.4	1
66	Image-guided cancer immunotherapy. , 2022, , 427-467.		0
67	Identification of characteristic subepithelial surface granulomatosis in immune-related adverse event-associated enterocolitis. <i>Cancer Science</i> , 2021, 112, 1320-1325.	1.7	10
68	Gastrointestinal Tract Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 247-253.	0.8	5
69	Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists. <i>Abdominal Radiology</i> , 2020, 45, 2624-2636.	1.0	8
70	Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. <i>International Immunopharmacology</i> , 2020, 84, 106601.	1.7	35
71	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series. <i>American Journal of Kidney Diseases</i> , 2020, 76, 299-302.	2.1	19
72	Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis. <i>Annals of Gastroenterology</i> , 2020, 34, 46-52.	0.4	2
73	Thymosin α 1 protects from CTLA-4 intestinal immunopathology. <i>Life Science Alliance</i> , 2020, 3, e202000662.	1.3	15

#	ARTICLE	IF	CITATIONS
74	Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. <i>World Journal of Clinical Oncology</i> , 2019, 10, 350-357.	0.9	11
75	Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 700-708.	2.3	19
76	A Case of Immune Checkpoint Inhibitor Refractory Colitis Treated with Mycophenolate and High-dose Steroids. <i>Cureus</i> , 2019, 11, e6392.	0.2	4
77	Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. <i>Supportive Care in Cancer</i> , 2022, 30, 2919-2931.	1.0	8
78	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. <i>Biomedicines</i> , 2021, 9, 1484.	1.4	10
79	Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. <i>World Journal of Clinical Oncology</i> , 2019, 10, 349-356.	0.9	0
80	Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis. <i>Cureus</i> , 2020, 12, e8613.	0.2	7
81	Gut microbiome and checkpoint inhibitor colitis. <i>Intestinal Research</i> , 2021, 19, 360-364.	1.0	14
82	Imaging Spectrum of Infections in the Setting of Immunotherapy and Molecular Targeted Therapy. <i>Current Problems in Diagnostic Radiology</i> , 2022, 51, 86-97.	0.6	1
83	Optimizing Care for Patients With Adverse Events From Immunotherapeutics. <i>Cancer Journal (Sudbury, Tj ETQq1 1.0, 784314 rgBT /Ove</i>	1.0	0
84	Diagnosis and Management of Immune Checkpoint Inhibitor Colitis. <i>Gastroenterology and Hepatology</i> , 2021, 17, 358-366.	0.2	3
85	Gastrointestinal adverse events of immunotherapy. <i>BJR Open</i> , 2021, 3, .	0.4	0
86	Atezolizumab-associated colitis mimic inflammatory bowel disease: a case report. <i>Advances in Digestive Medicine</i> , 0, .	0.1	1
87	Nanovesicle-Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects. <i>Advanced Materials</i> , 2022, 34, e2106516.	11.1	26
89	Checkpoint Inhibitors and the Gut. <i>Journal of Clinical Medicine</i> , 2022, 11, 824.	1.0	7
90	New-Onset Diarrheal Illness in a Patient With Ulcerative Colitis Receiving Nivolumab for Lung Adenocarcinoma. <i>Infectious Diseases in Clinical Practice</i> , 2022, 30, .	0.1	1
91	Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. <i>Frontiers in Immunology</i> , 2021, 12, 800879.	2.2	54
92	Immune checkpoint inhibitor colitis with concurrent cytomegalovirus reactivation. <i>Internal Medicine Journal</i> , 2022, 52, 504-505.	0.5	0

#	ARTICLE	IF	CITATIONS
93	Drug-Related Enteropathy. , 0, , .		1
94	Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors. <i>Clinical and Translational Science</i> , 2022, 15, 1430-1438.	1.5	2
95	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. <i>Chemotherapy</i> , 2023, 68, 1-15.	0.8	0
96	Acute Kidney Injury in Critically Ill Patients with Cancer. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 1385-1398.	2.2	11
97	Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors. <i>Life</i> , 2021, 11, 1387.	1.1	6
98	Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. <i>World Journal of Experimental Medicine</i> , 2021, 11, 79-92.	0.9	8
99	Immunotherapy-induced Colitis. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.1	5
100	Real-world data on the incidence of immune-related adverse events associated with anti-PD-1/PD-L1 treatment in Russia. <i>Voprosy Onkologii</i> , 2022, 68, 188-199.	0.1	3
101	A bilateral aseptic pyogenic ventriculitis following a course of pembrolizumab, an anti-PD-1 immune checkpoint inhibitor treatment for metastatic small cell lung cancer*. <i>Therapie</i> , 2022, , .	0.6	1
102	Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2022, 13, 779691.	2.2	100
103	Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events. <i>Annals of Pharmacotherapy</i> , 0, , 106002802210943.	0.9	1
104	Refractory Fulminant Colitis Requiring Surgical Intervention in a Patient With Ulcerative Colitis on Atezolizumab Therapy for Small Cell Lung Cancer: An Atypical Case. <i>Cureus</i> , 2022, , .	0.2	1
105	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	1.7	29
106	Immune Checkpoint Inhibitor Use in Microscopic Colitis. , 2022, 1, .		0
107	Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	42
108	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	1.1	6
109	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists's Perspectives. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 244-253.	0.2	1
110	Clinical Characteristics and Outcomes of Gastritis Associated With Immune Checkpoint Inhibitors: Scoping Review. <i>Journal of Immunotherapy</i> , 2022, 45, 363-369.	1.2	5

#	ARTICLE	IF	CITATIONS
111	Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3637-3648.	1.2	4
112	Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 109, 102440.	3.4	28
113	<i>Gastroenterology (GI)</i> , 2022, , 81-96.		0
114	Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3965-3976.	1.2	2
115	Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, .	1.4	0
116	A Case of Hepatocellular Carcinoma Successfully Resumed Atezolizumab and Bevacizumab After Associated Grade 3 Diarrhea and Grade 2 Colitis: Case Report and Literature Review. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1281-1288.	1.0	2
117	Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 878-890.	2.4	3
118	PD-L1 antibodies-armed exosomal vaccine for enhanced cancer immunotherapy by simultaneously in situ activating T cells and blocking PD-1/PD-L1 axis. , 2022, 1, 100012.		6
119	A Review of Immune Checkpoint Blockade for the General Surgeon. <i>Journal of Surgical Research</i> , 2023, 281, 289-298.	0.8	3
120	PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
121	Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review. <i>World Journal of Clinical Oncology</i> , 0, 13, 929-942.	0.9	6
122	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. <i>American Journal of Gastroenterology</i> , 2022, 117, 1917-1932.	0.2	4
123	Antibiotics for lung disease and cancer. , 2022, , 299-305.		1
124	Check this out: treatment paradigms in immune-checkpoint inhibitor colitis. <i>Current Opinion in Gastroenterology</i> , 2023, 39, 43-49.	1.0	1
125	Multiple White Plaques in the Esophagus: A Possible Case of Esophageal Mucosal Alteration Associated With Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Cureus</i> , 2022, , .	0.2	1
126	Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. <i>Cancers</i> , 2023, 15, 84.	1.7	1
127	Radiologic assessment of tumor response to immunotherapy and its complications. , 2023, , 239-261.		0
128	Cyclosporine treatment for severe steroid refractory immune-mediated colitis in a patient with ulcerative colitis. <i>GastroenterologÏa Y HepatologÏa</i> , 2024, 47, 72-73.	0.2	0

#	ARTICLE	IF	CITATIONS
129	Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events. CKJ: Clinical Kidney Journal, 2023, 16, 939-951.	1.4	5
130	Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease. ACG Case Reports Journal, 2022, 9, e00900.	0.2	1
131	Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. International Journal of Molecular Sciences, 2023, 24, 2769.	1.8	7
132	Learning from the nexus of autoimmunity and cancer. Immunity, 2023, 56, 256-271.	6.6	4
133	The Role of Microbiota-Derived Vitamins in Immune Homeostasis and Enhancing Cancer Immunotherapy. Cancers, 2023, 15, 1300.	1.7	1
134	Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy. World Journal of Clinical Cases, 0, 11, 1458-1466.	0.3	0
135	Immunotherapy and Gastrointestinal Toxicities. Praxis, 2023, 112, 172-177.	0.2	1
136	Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab. ACG Case Reports Journal, 2022, 9, e00946.	0.2	7
137	The interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy. , 0, 2, .		0
138	Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?. Pharmaceutics, 2023, 15, 823.	2.0	1
139	[18F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy. Diagnostics, 2023, 13, 978.	1.3	4
140	Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota. Frontiers in Oncology, 0, 13, .	1.3	0
142	Kidney function while on immune checkpoint inhibitors: Trends in incidence of acute kidney injury, and its causes and outcomes. Journal of Onco-Nephrology, 2023, 7, 57-65.	0.3	2
143	Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
152	Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	24
156	A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyteâ€‘monocyte apheresis combination therapy. Clinical Journal of Gastroenterology, 0, , .	0.4	0
159	Diarrhoea in the Setting of Immune Checkpoint Inhibitor Therapy. , 2023, , 373-376.		0